Drug Resistance Updates
Volume 13, Issue 1 , Pages 44-56 , February 2010

The long road to colorectal cancer therapy: Searching for the right signals

  • Frédéric Hollande

      Affiliations

    • CNRS, UMR 5203, Institut de Génomique Fonctionnelle, Montpellier F-34094, France
    • INSERM, U661, Montpellier F-34094, France
    • Université Montpellier 1, Montpellier F-34094, France
    • Université Montpellier 2, Montpellier F-34094, France
    • Corresponding Author InformationCorresponding author at: CNRS, UMR 5203, Institut de Génomique Fonctionnelle, Montpellier F-34094, France. Tel.: +33 4 67 66 81 44.
    • ,
  • Julie Pannequin

      Affiliations

    • CNRS, UMR 5203, Institut de Génomique Fonctionnelle, Montpellier F-34094, France
    • INSERM, U661, Montpellier F-34094, France
    • Université Montpellier 1, Montpellier F-34094, France
    • Université Montpellier 2, Montpellier F-34094, France
    • ,
  • Dominique Joubert

      Affiliations

    • CNRS, UMR 5203, Institut de Génomique Fonctionnelle, Montpellier F-34094, France
    • INSERM, U661, Montpellier F-34094, France
    • Université Montpellier 1, Montpellier F-34094, France
    • Université Montpellier 2, Montpellier F-34094, France

Received 20 December 2009 ,Revised 25 January 2010 ,Accepted 26 January 2010.

References 

  1. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, et al. Incidence of hereditary non-polyposis colorectal cancer and the feasibility of molecular screening for the disease. New Engl. J. Med. 1998;338:1481–1487
  2. Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer. 2002;94:344–351
  3. Allegra CJ, Yothers G, O’Connell MJ, et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J. Clin. Oncol. 2009;27:3385–3390
  4. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008;26:1626–1634
  5. André T, Boni C, et al. Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. New Engl. J. Med. 2004;350:2343–2351
  6. Aschele C, Bergamo F, Lonardi S. Chemotherapy for operable and advanced colorectal cancer. Cancer Treat. Rev. 2009;35:509–516
  7. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 2010;
  8. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat. Rev. Drug Discov. 2006;5:997–1014
  9. Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature. 2007;449:1003–1007
  10. Barker N, Ridgway RA, van Es JH, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature. 2009;457:608–611
  11. Baselga J, Rosen N. Determinants of resistance to anti-epidermal growth factor receptor agents. J. Clin. Oncol. 2008;26:1582–1584
  12. Becker L, Huang Q, Mashimo H. Immunostaining of LGr5, an intestinal stem cell marker, in normal and premalignant human gatrointestinal tissue. Scientific World J. 2008;23:1168–1176
  13. Beier D, Rohrl S, Pillai DR, et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res. 2008;68:5706–5715
  14. Benistant C, Chapuis H, Roche S. A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene. 2000;19:5083–5090
  15. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer. 2008;8:592–603
  16. Bertagnolli MM. The forest and the trees: pathways and proteins as colorectal cancer biomarkers. J. Clin. Oncol. 2009;27:5866–5867
  17. Bianco R, Damiano V, Gelardi T, Daniele G, Ciardiello F, Tortora G. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. Curr. Pharm. Des. 2007;13:3358–3367
  18. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 2009;27:1122–1129
  19. Birchmeier C, Birchmeier W, Gherardi E, Van de Woude GF. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003;4:915–925
  20. Boland WK, Bebb G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin. Biol. Ther. 2009;9:1199–1206
  21. Bolen JB, Veillette A, Schwartz AM, DeSeau V, Rosen N. Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc. Natl. Acad. Sci. (U.S.A.). 1987;84:2251–2255
  22. Bordonaro M, Lazarova DL, Sartorelli AC. Hyperinduction of Wnt activity: a new paradigm for the treatment of colorectal cancer?. Oncol. Res. 2008;17:1–9
  23. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682–4689
  24. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells—an integrated concept of malignant tumour progression. Nat. Rev. Cancer. 2005;5:744–749
  25. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007;448:439–444
  26. Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how?. Br. J. Cancer. 2009;100:1704–1719
  27. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol. 2009;6:465–477
  28. Chen B, Dodge ME, Tang W, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 2009;5:100–107
  29. Chu E. New treatment strategies for metastatic colorectal cancer. CMP Med. 2008;
  30. Church J, Kiringoda R, LaGuardia L. Inherited colorectal cancer registries in the United States. Dis. Colon Rectum. 2004;47:674–678
  31. Comella P, Casaretti R, Avallone A, Franco L. Optimizing the management of metastatic colorectal cancer. Crit. Rev. Oncol. Hematol. 2009;
  32. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 2008;7:504–516
  33. Crawford Y, Ferrara N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res. 2009;335:261–269
  34. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell. 2009;15:21–34
  35. Croker AK, Allan AL. Cancer stem cells: implications for the progression and treatment of metastatic disease. J. Cell. Mol. Med. 2008;12:374–390
  36. Crosnier C, Stamataki D, Lewis J. Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. Nat. Rev. Genet. 2006;7:349–359
  37. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer. 2006;6:184–192
  38. Dalerba P, Dylla SJ, Park IK. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. (U.S.A.). 2007;104:10158–10163
  39. de Gramont A, Haller DG, Sargent DJ, Tabernero J, Matheson A, Schilsky RL. Toward efficient trials in colorectal cancer: the ARCAD clinical trials program. J. Clin. Oncol. 2009;
  40. Dehm SM, Bonham K. SRC gene expression in human cancer: the role of transcriptional activation. Biochem. Cell Biol. 2004;82:263–274
  41. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 2008;26:5705–5712
  42. Dylla SJ, Beviglia L, Park IK, et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One. 2008;3:e2428
  43. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232–239
  44. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767
  45. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967–974
  46. Fields AL, Keller A, Schwartzberg L, et al. Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J. Clin. Oncol. 2009;27:1941–1947
  47. Fisher GA, et al. A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. Clin. Cancer Res. 2008;14:7074–7079
  48. Fre S, Huyghe M, Mourikis P, Robine S, Louvard D, Artavanis-Tsakonas S. Notch signals control the fate of immature progenitor cells in the intestine. Nature. 2005;435:964–968
  49. Frost A, et al. J. Clin Oncol. 2008;26(May (20) suppl.):(Abstr 2558)
  50. Garlich JR, De P, Dey N, et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug. SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008;68:206–215
  51. Giannopoulou E, Antonacopoulou A, Floratou K, Papavassiliou AG, Kalofonos HP. Dual targeting of EGFR and HER-2 in colon cancer cell lines. Cancer Chemother. Pharmacol. 2009;63:973–981
  52. Goldfinger LE. Choose your own path: specificity in Ras GTPase signaling. Mol. Biosyst. 2008;4:293–299
  53. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135:1079–1099
  54. Grange JM, Stanford JL, Stanford CA. Campbell De Morgan's ‘Observations on cancer’, and their relevance today. J. R. Soc. Med. 2002;95:296–299
  55. Gravalos C, Garcia-Escobar I, Garcia-Alfonso P, Cassinello J, Malon D, Carrato A. Adjuvant chemotherapy for stages II, III and IV of colon cancer. Clin. Transl. Oncol. 2009;11:526–533
  56. Greenberg JI, Shields DJ, Barillas SG, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 2008;456:809–813
  57. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138:645–659
  58. Hakam A, Yeatman TJ, Lu L, Mora L, Marcet G, Nicosia SV, et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum. Pathol. 1999;30:1128–1133
  59. Hecht JR, Trarbach T, Jaeger E, et al. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J. Clin. Oncol. 2005;23:LBA3;(Abstract)
  60. Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat. Rev. 2009;35:262–271
  61. Herbst RS. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin. Investig. Drugs. 2002;11:837–849
  62. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313–323
  63. Hewish M, Chau I, Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat. Anticancer Drug Discov. 2009;4:54–72
  64. Hilgard P, Klenner T, Stekar J, Nossner G, Kutscher B, Engel J. D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur. J. Cancer. 1997;33:442–446
  65. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69:7507–7511
  66. Hsiao SJ, Smith S. Tankyrase function at telomeres, spindle poles, and beyond. Biochimie. 2008;90:83–92
  67. Hsu JY, Wakelee HA. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs. 2009;23:289–304
  68. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009;461:614–620
  69. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl. J. Med. 2004;350:2335–2342
  70. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin. Cancer Res. 2009;15:4220–4227
  71. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer. 2005;5:341–354
  72. Ibn-Sîna . The Canon of Medicine. Chicago: Kazi Publications; 1999;
  73. Jalving M, de Jong S, Koornstra JJ, et al. TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. Clin. Cancer Res. 2006;12:4350–4356
  74. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 2009;59:225–249
  75. Jiang BH, Liu LZ. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist. Updat. 2008;11:63–76
  76. Jones S, Chen WD, Parmigiani G, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl. Acad. Sci. (U.S.A.). 2008;105:4283–4288
  77. Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. New Engl. J. Med. 2007;357:2040–2048
  78. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell. 2005;7:513–520
  79. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 2003;21:60–65
  80. Kalderon D. Transducing the hedgehog signal. Cell. 2000;103:371–374
  81. Kammula US, Kuntz EJ, Francone TD, et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. 2007;248:219–228
  82. Karakosta A, Golias C, Charalabopoulos A, Peschos D, Batistatou A, Charalabopoulos K. Genetic models of human cancer as a multistep process. Paradigm models of colorectal cancer, breast cancer, and chronic myelogenous and acute lymphoblastic leukaemia. J. Exp. Clin. Cancer Res. 2005;24:505–514
  83. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat. Rev. Clin. Oncol. 2009;6:587–595
  84. Kitisin K, Mishra L. Molecular biology of colorectal cancer: new targets. Semin. Oncol. 2006;33:S14–23
  85. Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006;125:733–747
  86. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer. 2010;10:130–137
  87. Knudsen BS, Van de Woude G. Showering c-MET-dependent cancers with drugs. Curr. Opin. Genet. Dev. 2008;18:87–96
  88. Koehne C, Bajetta E, Lin E, Van Cutsem E, Hecht J, Douillard J, et al Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). J. Clin. Oncol. 2006;24:3508;(Abstract)
  89. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat. Rev. Drug Discov. 2007;6:541–555
  90. Kopetz S, Shah AN, Gallick GE. Src continues aging: current and future clinical directions. Clin. Cancer Res. 2007;13:7232–7236
  91. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC−/− colon carcinoma. Science. 1997;275:1784–1787
  92. Krupitskaya Y, Wakelee HA. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr. Opin. Invest. Drugs. 2009;10:597–605
  93. LaBonte MJ, Manegold PC, Wilson PM, Fazzone W, Louie SG, Lenz HJ, et al. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. Int. J. Cancer. 2009;125:2957–2969
  94. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J. Clin. Oncol. 2009;27:5924–5930
  95. Le Tourneau C, Vidal L, Siu LL. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. Drug Resist. Updat. 2008;11:99–109
  96. Li F, Tiede B, Massague J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res. 2007;17:3–14
  97. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 2008;100:672–679
  98. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene. 2009;28:3801–3813
  99. Lieberman DA. Clinical practice. Screening for colorectal cancer. New Engl. J. Med. 2009;361:1179–1187
  100. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 2008;26:374–379
  101. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009;8:627–644
  102. Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, et al. Phase I study of intravenous vascular endothelial growth factor Trap. Aflibercept, in patients with advanced solid tumors. J. Clin. Oncol. 2009;28:207–214
  103. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 2008;11:32–50
  104. Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist. 2007;12:443–450
  105. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J. Clin. Oncol. 2009;27:2622–2629
  106. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis and medicolegal ramifications. Clin. Genet. 2009;76:1–18
  107. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metast. Rev. 2003;22:309–325
  108. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms and diseases. Dev. Cell. 2009;17:9–26
  109. Mack GS. FDA holds court on post hoc data linking KRAS status to drug response. Nat. Biotechnol. 2009;27:110–112
  110. Mahalingam D, Keane M, Pirianov G, Mehmet H, Samali A, Szegezdi E. Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines. Br. J. Cancer. 2009;100:1415–1424
  111. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 2008;7:1851–1863
  112. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J. Clin. Oncol. 2009;27:4027–4034
  113. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim. Biophys. Acta. 2008;1784:159–185
  114. Medina V, Calvo MB, Diaz-Prado S, Espada J. Hedgehog signalling as a target in cancer stem cells. Clin. Transl. Oncol. 2009;11:199–207
  115. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 2003;21:2787–2799
  116. Montagnani F, Migali C, Fiorentini G. Progression-free survival in bevacizumab-based first-line treatment for patients with metastatic colorectal cancer: is it a really good end point?. J. Clin. Oncol. 2009;27:e132–133(author reply e134–135)
  117. Monzo M, Moreno I, Artells R, et al. Sonic hedgehog mRNA expression by real-time quantitative PCR in normal and tumor tissues from colorectal cancer patients. Cancer Lett. 2006;233:117–123
  118. Morgillo F, Lee HY. Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist. Updat. 2005;8:298–310
  119. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275:1787–1790
  120. Mross K, Steinbild S, Baas F, et al. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur. J. Cancer. 2007;43:55–63
  121. Nakamura T, Tsuchiya K, Watanabe M. Crosstalk between Wnt and Notch signaling in intestinal epithelial cell fate decision. J. Gastroenterol. 2007;42:705–710
  122. O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106–110
  123. O’Connell MJ. Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in. J. Clin. Oncol. 2009;27:3082–3084
  124. Olaussen KA, Commo F, Tailler M, et al. Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines. Oncogene. 2009;28:4249–4260
  125. Olson JS. The History of Cancer; An Annotated Bibliography. Greenwood Press; 1989;
  126. O’Neil BH, Goldberg RM. Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. Oncologist. 2008;13:1074–1083
  127. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220–231
  128. Pinol V, Andreu M, Castells A, Paya A, Bessa X, Rodrigo J. Frequency of hereditary non-polyposis colorectal cancer and other colorectal cancer familial forms in Spain: a multicentre, prospective, nationwide study. Eur. J. Gastroenterol. Hepatol. 2004;16:39–45
  129. Pinto D, Clevers H. Wnt control of stem cells and differentiation in the intestinal epithelium. Exp. Cell Res. 2005;306:357–363
  130. Pozzo C, Barone C, Kemeny NE. Advances in neoadjuvant therapy for colorectal cancer with liver metastases. Cancer Treat. Rev. 2008;34:293–301
  131. Price TJ, Lipton L, McGreivy J, McCoy S, Sun YN, Rosenthal MA. Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours. Br. J. Cancer. 2008;99:1387–1394
  132. Punt CJ, Tol J. More is less—combining targeted therapies in metastatic colorectal cancer. Nat. Rev. Clin. Oncol. 2009;6:731–733
  133. Radtke F, Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science. 2005;307:1904–1909
  134. Rennel E, Waine E, Guan H, et al. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br. J. Cancer. 2008;98:1250–1257
  135. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–115
  136. Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J. Clin. Oncol. 2009;27:5931–5937
  137. Robarge KD, Brunton SA, Castanedo GM, et al. GDC-0449—a potent inhibitor of the hedgehog pathway. Bioorg. Med. Chem. Lett. 2009;19:5576–5581
  138. Rodilla V, Villanueva A, Obrador-Hevia A, et al. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc. Natl. Acad. Sci. (U.S.A.). 2009;106:6315–6320
  139. Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat. Rev. Drug Discov. 2006;5:1026–1033
  140. Rustgi AK. The genetics of hereditary colon cancer. Genes Dev. 2007;21:2525–2538
  141. Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J. Clin. Oncol. 2000;18:2193–2200
  142. Saltz LB, Rosen LS, Marshall JL, et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J. Clin. Oncol. 2007;25:4793–4799
  143. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554
  144. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098–1101
  145. Sato T, Vries RG, Snippert HJ, et al. Single LGr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459:262–265
  146. Schmidt M, De Maziere A, Smyczek T, Gray A, Parker L, Filvaroff E, et al. The role of Egfl7 in vascular morphogenesis. Novartis Found. Symp. 2007;283:18–28(discussion 28–36, 238–241)
  147. Schmoll HJ, Arnold D. When wishful thinking leads to a misty-eyed appraisal: the story of the adjuvant colon cancer trials with edrecolomab. J. Clin. Oncol. 2009;27:1926–1929
  148. Schneider BP, Radovich M, Miller KD. The role of vascular endothelial growth factor genetic variability in cancer. Clin. Cancer Res. 2009;15:5297–5302
  149. Segal NH, Saltz LB. Evolving treatment of advanced colon cancer. Annu. Rev. Med. 2009;60:207–219
  150. Shannon AM, Telfer BA, Smith PD, et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts. Clin. Cancer Res. 2009;15:6619–6629
  151. Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 2007;21:3214–3231
  152. Sharma S, Abhyankar V, Burgess RE, et al. A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann. Oncol. 2009;
  153. Shojaei F, Ferrara N. Role of the microenvironment in tumor growth and in refractractoriness/resistance to anti-angiogenic therapies. Drug Resist. Updat. 2008;11:219–230
  154. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl. Cancer Inst. 2009;101:1308–1324
  155. Snippert HJ, van Es JH, van den Born M, et al. Prominin-1/CD133 marks stem cells and early progenitors in mouse small intestine. Gastroenterology. 2009;136:2187–2194
  156. Spicer J. Technology evaluation: nimotuzumab, the Center of Molecular Immunology/YM BioSciences/Oncoscience. Curr. Opin. Mol. Ther. 2005;7:182–191
  157. Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature. 2008;456:814–818
  158. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature. 2001;411:349–354
  159. Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y. Colorectal cancer: genetics of development and metastasis. J. Gastroenterol. 2006;41:185–192
  160. Takeuchi H, Bilchik A, Saha S, et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin. Cancer Res. 2003;9:1480–1488
  161. Termuhlen PM, Curley SA, Talamonti MS, Saboorian MH, Gallick GE. Site-specific differences in pp60c-src activity in human colorectal metastases. J. Surg. Res. 1993;54:293–298
  162. Tol J, Koopman M, Rodenburg CJ, Cats A, Creemers GJ, Schrama JG, et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann. Oncol. 2008;19:734–738
  163. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol. 2009;27:5800–5807
  164. Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, et al. Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist. Updat. 2007;10:81–100
  165. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat. Rev. Cancer. 2002;2:289–300
  166. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J. Clin. Oncol. 2007;25:4000;(Abstract)
  167. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 2007;25:1658–1664
  168. Van Cutsem E, Köhne CH, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New Engl. J. Med. 2009;360:1408–1417
  169. Van den Eynde M, Hendlisz A. Treatment of colorectal liver metastases: a review. Rev. Recent Clin. Trials. 2009;4:56–62
  170. Van der Flier LG, Sabates-Bellver J, Oving I, Haegebarth A, De Palo M, Anti M, et al. The intestinal Wnt/TCF signature. Gastroenterology. 2007;132:628–632
  171. Van Es JH, Clevers H. Notch and Wnt inhibitors as potential new drugs for intestinal neoplastic disease. Trends Mol. Med. 2005;11:496–502
  172. Varjosalo M, Taipale J. Hedgehog signaling. J. Cell Sci. 2007;120:3–6
  173. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer. 2002;2:489–501
  174. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. New Engl. J. Med. 2009;361:1164–1172
  175. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002;62:5749–5754
  176. Wang Y, Sun Y. Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis. Curr. Cancer Drug Targets. 2002;2:191–207
  177. Weber MM, Fottner C, Liu SB, Jung MC, Engelhardt D, Baretton GB. Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer. 2002;95:2086–2095
  178. Weinstein IB. Cancer. Addiction to oncogenes—the Achilles heal of cancer. Science. 2002;297:63–64
  179. Wheeler DL, Dunn EF. BB, a novel epidermal growth factor receptor inhibitor. Cancer Biol. Ther. 2009;8:1648–1650
  180. Wheeler DL, Iida M, Dunn EF. The role of Src in solid tumors. Oncologist. 2009;14:667–678
  181. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 2008;7:3129–3140
  182. Wolmark N, Yothers G, O’Connell MJ, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08. J. Clin. Oncol. 2009;27:LBA4;(Abstract)
  183. Wong JJ, Hawkins NJ, Ward RL. Colorectal cancer: a model for epigenetic tumorigenesis. Gut. 2007;56:140–148
  184. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000;60:2178–2189
  185. Woodburn JR, Barker AJ, Wakeling A, et al. 6-Amino-4-(3-methyiphenylamino)-quinazoline: an EGF receptor tyrosine kinase inhibitor with activity in a range of human tumour xenografts. Proc. Am. Soc. Clin. Oncol. 1996;390
  186. Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Van de Woude GF, Testa JR. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc. Natl. Acad. Sci. (U.S.A.). 2001;98:247–252
  187. Xu L, Duda DG, di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res. 2009;69:7905–7910
  188. Yamamoto N, Tamura T, Yamamoto N, et al. Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2009;64:1165–1172
  189. Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, et al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett. 2008;265:258–269
  190. Zhang Y, Laterra J, Pomper MG. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. Neoplasia. 2009;11:96–101
  191. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 2009;8:806–823

PII: S1368-7646(10)00004-X

doi: 10.1016/j.drup.2009.01.002

Drug Resistance Updates
Volume 13, Issue 1 , Pages 44-56 , February 2010

Article Tools

* Image Usage & Resolution